Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acromegaly.

Annamaria Colao1, Ludovica F S Grasso2, Andrea Giustina3

  • 1Dipartimento di Medicina Clinica e Chirurgia, Sezione di Endocrinologia, University Federico II, Naples, Italy. colao@unina.it.

Nature Reviews. Disease Primers
|March 23, 2019
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European Reference Networks as core health structures where referring genetic newborn screening positive infants: an innovative operational research framework.

Frontiers in public health·2026
Same author

Distinct plasma protein profiles after long-term remission of Cushing's disease.

The Journal of clinical endocrinology and metabolism·2026
Same author

Consensus on acromegaly complications: an update.

Pituitary·2026
Same author

European Reference Networks - a flagship activity of the EU in the field of rare and complex diseases: from 2017 to 2025.

Orphanet journal of rare diseases·2026
Same author

Assessment of the 5-year evaluation for 1st call members of the European Reference Network on Rare Endocrine Conditions (Endo-ERN).

Endocrine connections·2026
Same author

The clinical value of [<sup>18</sup>F]-fluoro-ethyl-L-tyrosine PET ([<sup>18</sup>F]FET-PET) correlated with MRI in patients with functioning pituitary adenomas: an observational cohort study.

Pituitary·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Accidental hypothermia.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Primary aldosteronism.

Nature reviews. Disease primers·2026
Same journal

Buruli ulcer in Africa: between innovation and pragmatism.

Nature reviews. Disease primers·2026
Same journal

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
See all related articles
This summary is machine-generated.

Acromegaly, caused by excess growth hormone and IGF1, leads to disfigurement and health issues. Advances in treatments, including medical therapies like somatostatin receptor ligands, improve patient outcomes and reduce mortality.

Area of Science:

  • Endocrinology
  • Oncology
  • Medical Research

Background:

  • Acromegaly results from excess growth hormone (GH) and insulin-like growth factor I (IGF1), typically due to pituitary adenomas.
  • Chronic GH/IGF1 excess causes significant somatic and systemic complications, increasing mortality.
  • Increased disease awareness and diagnostic tools contribute to a reported rise in acromegaly incidence.

Purpose of the Study:

  • To review current understanding of acromegaly pathogenesis.
  • To discuss advancements in acromegaly management, including surgical, radiotherapeutic, and medical approaches.
  • To highlight available and emerging medical therapies for improved disease control.

Main Methods:

  • Review of scientific literature on acromegaly pathogenesis and treatment.

Related Experiment Videos

  • Analysis of current and developing therapeutic strategies.
  • Synthesis of information on medical treatments including somatostatin receptor ligands, dopamine agonists, and GH receptor antagonists.

    • Main Results:

    • Acromegaly treatment has evolved, with medical therapies becoming a crucial option, even for first-line use.
    • Pharmacological options include somatostatin receptor ligands (octreotide, lanreotide, pasireotide), dopamine agonists, and pegvisomant.
    • Optimal treatment strategies aim to normalize mortality rates to those of the general population.

    Conclusions:

    • Effective management of acromegaly, particularly through advanced medical therapies, is key to reducing associated mortality.
    • New medical therapies and a deeper understanding of pathogenesis offer improved disease control.
    • Continued research into acromegaly pathogenesis and treatment development is essential.